Inogen Earnings Call Transcripts
Fiscal Year 2026
-
Directors and auditors were elected and ratified, executive compensation and the equity plan were approved, but the proposal to declassify the board did not pass. The meeting concluded with a Q&A session addressing forward-looking risks.
-
Q1 2026 revenue grew 3.4% year-over-year to $85.1 million, led by 18% international growth, while U.S. sales declined. New product launches and international expansion are expected to drive full-year growth, with profitability improvements anticipated in Q2 and Q3.
-
Leadership expansion and strategic hires support transformation into a broader respiratory care platform. New product launches, including Voxi 5, Simeox, and Aurora masks, are expected to drive growth and margin improvement, while B2B channel gains offset DTC headwinds. Share repurchases and disciplined spending reinforce a focus on shareholder value.
-
Management outlined a successful transformation to a diversified portfolio, expanding TAM and returning to profitable growth. New products and international expansion are expected to drive 6% revenue growth in 2026, with a focus on margin improvement and high single-digit growth over the next 3–5 years.
Fiscal Year 2025
-
Delivered 4% revenue growth in 2025, returned to positive adjusted EBITDA, and launched new products expanding the addressable market to $3.4B. Guidance for 2026 targets 6% revenue growth and continued profitability, supported by a $30M share repurchase program.
-
Q3 2025 saw 4% revenue growth to $92.4M, led by strong international B2B gains and improved profitability. New product launches and disciplined cost management supported a raised full-year adjusted EBITDA outlook, with continued focus on innovation and global expansion.
-
Q2 2025 saw 4% revenue growth to $92.3M, driven by strong B2B channels and a 19% unit volume increase. Gross margin was 44.8%, and adjusted EBITDA reached $2.1M. Full-year guidance was raised, with VOXY-5 and digital health launches expanding the addressable market.
-
Q1 2025 revenue grew 5.5% year-over-year to $82.3 million, led by strong B2B channel gains, while DTC and rental segments declined but showed signs of stabilization. Adjusted EBITDA turned positive, and full-year guidance was reaffirmed, with no significant tariff impact expected.
-
Leadership restructuring and strategic partnerships have set the stage for growth, with new product launches and a focus on digital health. Expansion into China and the introduction of new devices are expected to drive future profitability, while operational efficiencies and cost controls support improved margins.
Fiscal Year 2024
-
Full-year 2024 revenue grew 6.4% to $335.7M, led by strong B2B performance and new product launches. The Yuwell partnership and FDA clearance for Simeox expand global reach, while 2025 guidance targets 5–6% revenue growth and near break-even adjusted EBITDA.
-
COPD remains a major global health challenge, with significant market potential for portable oxygen solutions. Recent product launches and acquisitions expand the portfolio, while a refreshed leadership team drives profitability and innovation. Regulatory and reimbursement efforts for new devices are ongoing.
-
New leadership has driven a cultural and operational turnaround, focusing on profitable growth, channel optimization, and innovation. B2B and DTC channels are being restructured for margin improvement, while the Simeox device represents a strategic pipeline expansion.
-
Q3 2024 revenue grew 5.8% year-over-year to $88.8 million, driven by strong B2B sales, while DTC revenue declined but became more profitable. Gross margin improved to 46.5%, and the company posted a second consecutive quarter of positive cash flow.
-
Q2 2024 revenue grew 6.1% year-over-year to $88.8 million, led by strong B2B sales, while DTC and rental segments declined. Gross margin improved to 48.1% with positive Adjusted EBITDA, but guidance for the second half is cautious due to expected advertising headwinds.